GlassScriptPhysician profile
Amanda Rouse Whitman
NPI 1700611894
$2,266.73
in general payments reported to CMS, 2019-2025
31 companies · $1,953 in 2025
The $1,953 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $313 · 2025: $1,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $233.82 | 2025 | Twiist |
| Lundbeck LLC | $198.53 | 2024-2025 | Vyepti |
| Medtronic, INC. | $158.07 | 2024 | Minimed 780g |
| Lilly USA, LLC | $157.47 | 2025 | Zepbound, Mounjaro, Amyvid |
| Neurelis, INC. | $153.55 | 2024-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $135.43 | 2025 | Motpoly Xr |
| Corcept Therapeutics | $135.39 | 2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $123.43 | 2024-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $102.82 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.37 | 2025 | Jardiance, Ofev |
| Beta Bionics, INC. | $89.08 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ucb, INC. | $87.79 | 2024-2025 | Nayzilam, Briviact |
| Cequr Corporation | $70.49 | 2024-2025 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $69.31 | 2025 | Dupixent |
| Novo Nordisk INC | $53.42 | 2025 | Rybelsus, Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $48.96 | 2025 | Ocrevus Zunovo, Ocrevus |
| Inspire Medical Systems, INC. | $39.30 | 2025 | Inspire |
| Amgen INC. | $38.06 | 2025 | Tepezza |
| Sanofi-Aventis U.S. LLC | $30.05 | 2025 | |
| Verona Pharma, INC. | $28.63 | 2025 | Ohtuvayre |
| Sk Life Science, INC. | $28.53 | 2025 | |
| Inogen, INC. | $25.67 | 2025 | |
| Emd Serono, INC. | $23.25 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2025 | |
| Philips North America LLC | $19.69 | 2025 | Vest Therapy Und |
| Electromed, INC. | $18.51 | 2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $17.19 | 2025 | Fasenra |
| Recordati_rare_diseases_inc. | $17.13 | 2025 | Isturisa |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2025 | Rexulti |
| Mannkind Corporation | $13.83 | 2025 | |
| Xeris Pharmaceuticals, INC. | $13.62 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Whitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.